People
Biopharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.
Plurisitem Therapeutics’ PLX (Placental eXpanded) cells are showing promise as a therapy for patients with severe cases of COVID-19.
On March 16, Moderna and the National Institute of Allergy and Infectious Disease (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 23, 2020.
In a statement to the New York Times, Bright said he has pushed for science, not politics, as the key to battling the pandemic.
After leading a flurry of collaborations with multiple companies to hasten the development of vaccine candidates and treatments for COVID-19, Rick Bright, the director of BARDA, has abruptly departed his post for another position in the government.
Relmada Therapeutics is working to develop a treatment, REL-1017, for those with depression that do not respond to drugs currently on the market.
At least some of the concern is that without greater funding and coordination, the companies won’t be able to buy sufficient raw materials, continue production of existing drugs and quickly scale up their capacity to meet the demand of new drugs and older therapies around the world.
The Rockefeller Foundation laid out its COVID-19 Testing Action Plan as a fundamental step to reopen the country.
Traditional vaccine development and regulatory policies are changing in response to the current pandemic. Some of those approaches may become more common, expanding into other, non-pandemic-related areas in the future.
PRESS RELEASES